Find and Pitch Jounalists, Get Your Story Covered

Tags: Emerging Therapies Momelotinib Myelofibrosis Pharmacists Anemia

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	MHRA grants approval for bladder cancer drug erdafitinib - 9 days ago
2	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials - 2 months ago
3	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 2 months ago FDA Accepts NDA and Priority Review Application for Vimseltinib in Tenosynovial Giant Cell Tumors - 3 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 3 months ago FDA Approves Rybrevant as First-Line Treatment for NSCLC - 9 months ago FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC - 9 months ago FDA Grants Accelerated Approval to Lifileucel For Treatment of Advanced Melanoma - 9 months ago FDA Grants Orphan Drug Designation to Tigilanol Tiglate for Soft Tissue Sarcoma - 9 months ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - 11 months ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - 12 months ago FDA Approves Repotrectinib for Treatment of ROS1-Positive NSCLC - 12 months ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - about 1 year ago FDA Grants Priority Review to New Drug Application for Belzutifan for Advanced Renal Cell Carcinoma - about 1 year ago
4	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Grants Regenerative Medicine Advanced Therapy Designation for OBX-115 - 2 months ago Utidelone Injectable Granted FDA Orphan Drug Designation for Breast Cancer Brain Metastasis - 8 months ago
5	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 3 months ago FDA OKs First Cellular Therapy for Melanoma - 9 months ago FDA Approves Belzutifan for Advanced Renal Cell Carcinoma - 11 months ago Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations - 12 months ago FDA OKs New Option for Advanced ROS1-Positive Lung Cancer - 12 months ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - about 1 year ago RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer - about 1 year ago RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC - about 1 year ago
6	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 4 months ago TIL Therapy May Offer Novel Approach for Metastatic Lung Cancer - 4 months ago Novel TKI Promising in Early Study of HER2-Mutant NSCLC - 5 months ago Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma - 10 months ago Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T - 10 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 11 months ago Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years - 11 months ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - 12 months ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - 12 months ago
7	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Geron Drug Lands a First-in-Class FDA Approval in Type of Blood Cancer - 5 months ago
8	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 9 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - 11 months ago Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial - 11 months ago Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia - 11 months ago Non-Covalent BTK Inhibitor Approved for CLL - 12 months ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - about 1 year ago Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years - about 1 year ago
9	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - 9 months ago FDA Grants Priority Review to Repotrectinib for the Treatment of NTRK-Positive Solid Tumors - 9 months ago
10	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Therapies - 10 months ago

Journalists covering Momelotinib